Which has preferable earnings and valuation, LH or HSIC?

Labcorp has higher revenue and earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Labcorp $13.95B 1.95 $876.50M $12.09 27.78 Henry Schein $13.18B 0.76 $398M $3.43 26.10

Is LH or HSIC more profitable?

Labcorp has a net margin of 6.99% compared to Henry Schein's net margin of 2.96%. Labcorp's return on equity of 16.74% beat Henry Schein's return on equity. Company Net Margins Return on Equity Return on Assets Labcorp 6.99% 16.74% 7.81% Henry Schein 2.96% 15.97% 5.56%

Does the media favor LH or HSIC?

In the previous week, Henry Schein had 4 more articles in the media than Labcorp. MarketBeat recorded 14 mentions for Henry Schein and 10 mentions for Labcorp. Henry Schein's average media sentiment score of 0.60 beat Labcorp's score of 0.42 indicating that Henry Schein is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Henry Schein 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, MEDP or LH?

Labcorp has higher revenue and earnings than Medpace. Labcorp is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.78B 6.03 $451.12M $17.06 35.21 Labcorp $13.95B 1.95 $876.50M $12.09 27.78

Is MEDP or LH more profitable?

Medpace has a net margin of 17.67% compared to Labcorp's net margin of 6.99%. Medpace's return on equity of 110.15% beat Labcorp's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% Labcorp 6.99% 16.74% 7.81%

Does the media refer more to MEDP or LH?

In the previous week, Medpace had 35 more articles in the media than Labcorp. MarketBeat recorded 45 mentions for Medpace and 10 mentions for Labcorp. Medpace's average media sentiment score of 1.10 beat Labcorp's score of 0.42 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 32 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Labcorp 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LH or AMN?

In the previous week, AMN Healthcare Services had 10 more articles in the media than Labcorp. MarketBeat recorded 20 mentions for AMN Healthcare Services and 10 mentions for Labcorp. AMN Healthcare Services' average media sentiment score of 0.43 beat Labcorp's score of 0.42 indicating that AMN Healthcare Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AMN Healthcare Services 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, LH or BIO?

Labcorp has higher revenue and earnings than Bio-Rad Laboratories. Labcorp is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Labcorp $13.95B 1.95 $876.50M $12.09 27.78 Bio-Rad Laboratories $2.58B 4.02 $759.90M $8.25 47.07

Does the media favor LH or BIO?

In the previous week, Bio-Rad Laboratories had 3 more articles in the media than Labcorp. MarketBeat recorded 13 mentions for Bio-Rad Laboratories and 10 mentions for Labcorp. Labcorp's average media sentiment score of 0.42 beat Bio-Rad Laboratories' score of 0.02 indicating that Labcorp is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bio-Rad Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, CAH or LH?

Cardinal Health has higher revenue and earnings than Labcorp. Labcorp is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardinal Health $254.25B 0.21 $1.71B $7.23 32.46 Labcorp $13.95B 1.95 $876.50M $12.09 27.78

Does the media favor CAH or LH?

In the previous week, Cardinal Health had 33 more articles in the media than Labcorp. MarketBeat recorded 43 mentions for Cardinal Health and 10 mentions for Labcorp. Cardinal Health's average media sentiment score of 1.37 beat Labcorp's score of 0.42 indicating that Cardinal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardinal Health 38 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Labcorp 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Labcorp (LH) Competitors

$335.90 -0.64 (-0.19%)

As of 08/28/2026 03:58 PM Eastern

Compare

LH vs. HSIC, MEDP, AMN, BIO, and CAH

Should you buy Labcorp stock or one of its competitors? Labcorp's main competitors and comparable companies include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Bio-Rad Laboratories (BIO), and Cardinal Health (CAH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Labcorp compare to Henry Schein?

Labcorp (NYSE:LH) and Henry Schein (NASDAQ:HSIC) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Labcorp has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 96.6% of Henry Schein shares are owned by institutional investors. 0.8% of Labcorp shares are owned by insiders. Comparatively, 0.9% of Henry Schein shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Henry Schein had 4 more articles in the media than Labcorp. MarketBeat recorded 14 mentions for Henry Schein and 10 mentions for Labcorp. Henry Schein's average media sentiment score of 0.60 beat Labcorp's score of 0.42 indicating that Henry Schein is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Henry Schein	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Labcorp presently has a consensus price target of $330.00, suggesting a potential downside of 1.76%. Henry Schein has a consensus price target of $92.93, suggesting a potential upside of 3.81%. Given Henry Schein's higher possible upside, analysts clearly believe Henry Schein is more favorable than Labcorp.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Henry Schein	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53

Labcorp has a net margin of 6.99% compared to Henry Schein's net margin of 2.96%. Labcorp's return on equity of 16.74% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.99%	16.74%	7.81%
Henry Schein	2.96%	15.97%	5.56%

Labcorp has higher revenue and earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.95	$876.50M	$12.09	27.78
Henry Schein	$13.18B	0.76	$398M	$3.43	26.10

Summary

Labcorp beats Henry Schein on 10 of the 15 factors compared between the two stocks.

How does Labcorp compare to Medpace?

Medpace (NASDAQ:MEDP) and Labcorp (NYSE:LH) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Labcorp has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Medpace has a net margin of 17.67% compared to Labcorp's net margin of 6.99%. Medpace's return on equity of 110.15% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Labcorp	6.99%	16.74%	7.81%

Labcorp has higher revenue and earnings than Medpace. Labcorp is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.78B	6.03	$451.12M	$17.06	35.21
Labcorp	$13.95B	1.95	$876.50M	$12.09	27.78

Medpace currently has a consensus price target of $584.18, indicating a potential downside of 2.74%. Labcorp has a consensus price target of $330.00, indicating a potential downside of 1.76%. Given Labcorp's stronger consensus rating and higher probable upside, analysts clearly believe Labcorp is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Medpace had 35 more articles in the media than Labcorp. MarketBeat recorded 45 mentions for Medpace and 10 mentions for Labcorp. Medpace's average media sentiment score of 1.10 beat Labcorp's score of 0.42 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	32 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Labcorp	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.0% of Medpace shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 0.8% of Labcorp shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Medpace beats Labcorp on 10 of the 16 factors compared between the two stocks.

How does Labcorp compare to AMN Healthcare Services?

Labcorp (NYSE:LH) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 0.8% of Labcorp shares are owned by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Labcorp has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Labcorp presently has a consensus target price of $330.00, indicating a potential downside of 1.76%. AMN Healthcare Services has a consensus target price of $31.43, indicating a potential downside of 9.06%. Given Labcorp's stronger consensus rating and higher possible upside, research analysts plainly believe Labcorp is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, AMN Healthcare Services had 10 more articles in the media than Labcorp. MarketBeat recorded 20 mentions for AMN Healthcare Services and 10 mentions for Labcorp. AMN Healthcare Services' average media sentiment score of 0.43 beat Labcorp's score of 0.42 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AMN Healthcare Services	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Labcorp has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.95	$876.50M	$12.09	27.78
AMN Healthcare Services	$2.73B	0.49	-$95.70M	$2.68	12.90

Labcorp has a net margin of 6.99% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Labcorp's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.99%	16.74%	7.81%
AMN Healthcare Services	3.06%	19.92%	5.93%

Summary

Labcorp beats AMN Healthcare Services on 11 of the 16 factors compared between the two stocks.

How does Labcorp compare to Bio-Rad Laboratories?

Labcorp (NYSE:LH) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

In the previous week, Bio-Rad Laboratories had 3 more articles in the media than Labcorp. MarketBeat recorded 13 mentions for Bio-Rad Laboratories and 10 mentions for Labcorp. Labcorp's average media sentiment score of 0.42 beat Bio-Rad Laboratories' score of 0.02 indicating that Labcorp is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bio-Rad Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Labcorp has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Labcorp currently has a consensus target price of $330.00, indicating a potential downside of 1.76%. Bio-Rad Laboratories has a consensus target price of $343.33, indicating a potential downside of 11.58%. Given Labcorp's stronger consensus rating and higher probable upside, equities analysts plainly believe Labcorp is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Labcorp has higher revenue and earnings than Bio-Rad Laboratories. Labcorp is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.95	$876.50M	$12.09	27.78
Bio-Rad Laboratories	$2.58B	4.02	$759.90M	$8.25	47.07

Bio-Rad Laboratories has a net margin of 8.59% compared to Labcorp's net margin of 6.99%. Labcorp's return on equity of 16.74% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.99%	16.74%	7.81%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

95.9% of Labcorp shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 0.8% of Labcorp shares are held by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Labcorp beats Bio-Rad Laboratories on 10 of the 16 factors compared between the two stocks.

How does Labcorp compare to Cardinal Health?

Cardinal Health (NYSE:CAH) and Labcorp (NYSE:LH) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Cardinal Health has higher revenue and earnings than Labcorp. Labcorp is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardinal Health	$254.25B	0.21	$1.71B	$7.23	32.46
Labcorp	$13.95B	1.95	$876.50M	$12.09	27.78

Cardinal Health pays an annual dividend of $2.06 per share and has a dividend yield of 0.9%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.9%. Cardinal Health pays out 28.5% of its earnings in the form of a dividend. Labcorp pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has raised its dividend for 29 consecutive years. Cardinal Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Labcorp has a net margin of 6.99% compared to Cardinal Health's net margin of 0.67%. Labcorp's return on equity of 16.74% beat Cardinal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardinal Health	0.67%	-98.53%	4.69%
Labcorp	6.99%	16.74%	7.81%

Cardinal Health has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

87.2% of Cardinal Health shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 0.1% of Cardinal Health shares are owned by company insiders. Comparatively, 0.8% of Labcorp shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cardinal Health currently has a consensus price target of $266.56, indicating a potential upside of 13.57%. Labcorp has a consensus price target of $330.00, indicating a potential downside of 1.76%. Given Cardinal Health's stronger consensus rating and higher possible upside, research analysts plainly believe Cardinal Health is more favorable than Labcorp.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardinal Health	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.84
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Cardinal Health had 33 more articles in the media than Labcorp. MarketBeat recorded 43 mentions for Cardinal Health and 10 mentions for Labcorp. Cardinal Health's average media sentiment score of 1.37 beat Labcorp's score of 0.42 indicating that Cardinal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardinal Health	38 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Labcorp	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cardinal Health beats Labcorp on 10 of the 19 factors compared between the two stocks.

Get Labcorp News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LH vs. The Competition

Export

Metric	Labcorp	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$27.18B	$9.87B	$7.20B	$24.19B
Dividend Yield	0.86%	2.56%	2.54%	3.71%
P/E Ratio	27.78	34.69	273.16	29.99
Price / Sales	1.95	4.96	634.19	19.47
Price / Cash	13.50	120.59	76.74	32.24
Price / Book	3.16	4.00	12.98	7.67
Net Income	$876.50M	$312.92M	$3.48B	$1.07B
7 Day Performance	-0.04%	-1.34%	0.13%	-0.32%
1 Month Performance	6.38%	0.93%	7.08%	1.84%
1 Year Performance	20.80%	15.34%	24.67%	13.37%

Labcorp Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LH Labcorp	4.0627 of 5 stars	$335.90 -0.2%	$330.00 -1.8%	+20.8%	$27.18B	$13.95B	27.78	71,000
HSIC Henry Schein	2.3071 of 5 stars	$89.52 -0.3%	$92.27 +3.1%	+28.7%	$10.00B	$13.18B	26.10	25,000	Analyst Revision
MEDP Medpace	3.1816 of 5 stars	$597.12 +3.2%	$584.18 -2.2%	+26.3%	$16.15B	$2.53B	35.00	6,200	News Coverage Insider Trade
AMN AMN Healthcare Services	2.2277 of 5 stars	$34.46 -0.1%	$31.43 -8.8%	+66.4%	$1.34B	$2.73B	12.86	2,664	Trending News Analyst Downgrade Analyst Revision
BIO Bio-Rad Laboratories	1.6332 of 5 stars	$355.06 -0.3%	$343.33 -3.3%	+30.1%	$9.53B	$2.58B	43.04	7,450	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:LH) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Labcorp (LH) Competitors

LH vs. HSIC, MEDP, AMN, BIO, and CAH

How does Labcorp compare to Henry Schein?

Summary

How does Labcorp compare to Medpace?

Summary

How does Labcorp compare to AMN Healthcare Services?

Summary

How does Labcorp compare to Bio-Rad Laboratories?

Summary

How does Labcorp compare to Cardinal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LH vs. The Competition

Labcorp Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Labcorp (LH) Competitors

LH vs. HSIC, MEDP, AMN, BIO, and CAH

How does Labcorp compare to Henry Schein?

Which has more volatility and risk, LH or HSIC?

Do insiders and institutionals have more ownership in LH or HSIC?

Does the media favor LH or HSIC?

Do analysts recommend LH or HSIC?

Is LH or HSIC more profitable?

Which has preferable earnings and valuation, LH or HSIC?

Summary

How does Labcorp compare to Medpace?

Which has more volatility and risk, MEDP or LH?

Is MEDP or LH more profitable?

Which has preferable valuation & earnings, MEDP or LH?

Do analysts rate MEDP or LH?

Does the media refer more to MEDP or LH?

Do institutionals and insiders believe in MEDP or LH?

Summary

How does Labcorp compare to AMN Healthcare Services?

Do institutionals & insiders believe in LH or AMN?

Which has more volatility & risk, LH or AMN?

Do analysts rate LH or AMN?

Does the media prefer LH or AMN?

Which has stronger earnings and valuation, LH or AMN?

Is LH or AMN more profitable?

Summary

How does Labcorp compare to Bio-Rad Laboratories?

Does the media favor LH or BIO?

Which has more volatility & risk, LH or BIO?

Do analysts prefer LH or BIO?

Which has preferable valuation and earnings, LH or BIO?

Is LH or BIO more profitable?

Do institutionals and insiders have more ownership in LH or BIO?

Summary

How does Labcorp compare to Cardinal Health?

Which has stronger valuation and earnings, CAH or LH?

Is CAH or LH a better dividend stock?

Is CAH or LH more profitable?

Which has more volatility and risk, CAH or LH?

Do institutionals & insiders have more ownership in CAH or LH?

Do analysts recommend CAH or LH?

Does the media favor CAH or LH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LH vs. The Competition

Labcorp Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools